Tate & Lyle Expands BioHarvest Sciences Partnership for Next-Gen Sweetener Innovation
BHST is trading near its 52-week low of $3.57 (15% above the low).
Summary
BioHarvest Sciences Inc. announced a significant expansion of its collaboration with Tate & Lyle PLC, a global leader in ingredient solutions. This expanded program will broaden the scope of their joint sweetener development to include multiple plant-based sweetener molecules, building on strong technical progress since their initial 2024 agreement. This development is highly positive as it validates BioHarvest's Botanical Synthesis™ platform through a deepened partnership with a major industry player. It positions the company to accelerate innovation in the high-demand market for healthier, plant-based sweetening solutions, potentially leading to substantial future commercial opportunities. Investors should watch for further milestones in the development and potential commercialization of these next-generation sweeteners.
At the time of this announcement, BHST was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $92.9M. The 52-week trading range was $3.57 to $12.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: TMX Newsfile.